Lupin Ltd. – FDA 483, May 15, 2019

This FDA Form 483 was issued to Lupin Limited in Aurangabad, India, following an inspection conducted from May 6th to May 19th. The inspection revealed significant deficiencies in the facility's quality system and manufacturing operations, particularly concerning the production of drug products.

**Key Observations:**

1. **Inadequate Investigation of Discrepancies:** The firm failed to thoroughly investigate unexplained discrepancies and the failure of a batch or any of its components to meet specifications. Specifically, the document notes that investigations into out-of-specification (OOS) results were not always conclusive or adequately addressed the root cause. This includes instances where retesting was performed without proper justification or where initial OOS results were invalidated without sufficient scientific rationale.

2. **Insufficient Process Control:** There was a lack of adequate control procedures to ensure the identity, strength, quality, and purity of drug products. This was evidenced by issues such as: * **Environmental Monitoring Deficiencies:** The environmental monitoring program in aseptic processing areas was found to be inadequate, potentially compromising the sterility of drug products. * **Sterilization Process Issues:** Concerns were raised regarding the validation and control of sterilization processes, indicating a potential risk of non-sterile products. * **Batch Record Inaccuracies:** Discrepancies and incomplete information were noted in batch production and control records, making it difficult to ensure consistent product quality.

3. **Lack of